Part 3.15 / M35 (Part 6/6)
3. DEEL 3: GEHARMONISEERDE INDELING EN ETIKETTERING
|
Catalogusnummer |
►M18 Chemische naam ◄ |
EG-nr. |
CAS-nr. |
Indeling |
Etikettering |
►M18 Specifieke concentratiegrenzen, M-factoren en ATE's (*1) ◄ |
Opmerkingen |
|||
|
Gevarenklasse en -categorie |
Gevarenaanduiding |
Pictogram, signaalwoord |
Gevarenaanduiding |
Aanvullende gevarenaanduiding |
||||||
|
607-034-00-0 |
methylacrylaat; methylpropenoaat |
202-500-6 |
Flam. Liq. 2 Acute Tox. 3 Acute Tox. 4 Acute Tox. 4 STOT SE 3 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1 |
H225 H331 H312 H302 H335 H315 H319 H317 |
GHS02 GHS06 Dgr |
H225 H331 H312 H302 H335 H315 H319 H317 |
|
inademing: ATE = 3 mg/l (dampen) dermaal: ATE = 1 100 mg/kg lg oraal: ATE = 500 mg/kg lg |
D |
|
|
607-223-00-8 |
transfluthrin (ISO); 2,3,5,6-tetrafluorbenzyl-(1R,3S)-3-(2,2-dichloorvinyl)-2,2-dimethylcyclopropaancarboxylaat |
405-060-5 |
Carc. 2 Acute Tox. 4 STOT SE 1 Aquatic Acute 1 Aquatic Chronic 1 |
H351 H302 H370 (zenuwstelsel) H400 H410 |
GHS08 GHS07 GHS09 Wng |
H351 H302 H370 (zenuwstelsel) H410 |
EUH066 |
oraal: ATE = 580 mg/kg lg M = 1 000 M = 1 000 |
|
|
|
607-246-00-3 |
allylmethacrylaat; 2-methyl-2-propeenzuur, 2-propenylester |
202-473-0 |
Flam. Liq. 3 Acute Tox. 2 Acute Tox. 3 Acute Tox. 4 Aquatic Acute 1 |
H226 H330 H311 H302 H400 |
GHS02 GHS06 GHS09 Dgr |
H226 H330 H311 H302 H400 |
|
inademing: ATE = 1,5 mg/l (dampen) dermaal: ATE = 300 mg/kg lg oraal: ATE = 400 mg/kg lg |
|
|
|
607-766-00-0 |
tetramethyleendimethacrylaat |
218-218-1 |
Skin Sens. 1B |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
|
607-767-00-6 |
7,7,9(of 7,9,9)-trimethyl-4,13-dioxo-3,14-dioxa-5,12-diazahexadecaan-1,16-diylbismethacrylaat |
276-957-5 |
Skin Sens. 1B |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
|
607-768-00-1 |
2,2'-ethyleendioxydiëthyldimethacrylaat |
203-652-6 |
Skin Sens. 1B |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
|
607-769-00-7 |
bifenox (ISO); methyl-5-(2,4-dichloorfenoxy)-2-nitrobenzoaat |
255-894-7 |
Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H400 H410 |
GHS07 GHS09 Wng |
H302 H410 |
|
oraal: ATE = 1 500 mg/kg lg M = 1 000 M = 1 000 |
|
|
|
612-004-00-5 |
triëthylamine |
204-469-4 |
Flam. Liq. 2 Acute Tox. 3 Acute Tox. 3 Acute Tox. 3 Skin Corr. 1A Eye Dam. 1 |
H225 H331 H311 H301 H314 H318 |
GHS02 GHS06 GHS05 Dgr |
H225 H331 H311 H301 H314 |
|
inademing: ATE = 7,2 mg/l (dampen) dermaal: ATE = 300 mg/kg lg oraal: ATE = 100 mg/kg lg STOT SE 3; H335: C ≥ 1 % |
|
|
|
612-049-00-0 |
di-n-butylamine |
203-921-8 |
Flam. Liq. 3 Acute Tox. 2 Acute Tox. 3 Acute Tox. 3 Skin Corr. 1B Eye Dam. 1 |
H226 H330 H311 H301 H314 H318 |
GHS02 GHS06 GHS05 Dgr |
H226 H330 H311 H301 H314 |
EUH 071 |
inademing: ATE = 1,2 mg/l (dampen) dermaal: ATE = 300 mg/kg lg oraal: ATE = 220 mg/kg lg |
|
|
|
612-056-00-9 |
N,N-dimethyl-m-toluïdine; [1] N,N-dimethyl-o-toluïdine [2] |
204-495-6 [1] 210-199-8 [2] |
Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Chronic 3 |
H331 H311 H301 H373 ** H412 |
GHS06 GHS08 Dgr |
H331 H311 H301 H373 ** H412 |
|
* |
C |
|
|
612-295-00-9 |
benfluralin (ISO); N-butyl-N-ethyl-α,α,α-trifluor-2,6-dinitro-p-toluïdine |
217-465-2 |
Carc. 2 Repr. 2 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H351 H361d H315 H319 H317 H400 H410 |
GHS08 GHS07 GHS09 Wng |
H351 H361d H315 H319 H317 H410 |
|
M = 10 M = 10 |
|
|
|
612-296-00-4 |
N,N-dimethyl-p-toluïdine |
202-805-4 |
Carc. 1B Acute Tox. 4 Acute Tox. 3 STOT RE 2 Aquatic Chronic 3 |
H350 H332 H301 H373 (bloed, luchtwegen) H412 |
GHS08 GHS06 Dgr |
H350 H332 H301 H373 (bloed, luchtwegen) H412 |
|
inademing: ATE = 1,4 mg/l (stofdeeltjes of nevels) oraal: ATE = 140 mg/kg lg |
|
|
|
612-297-00-X |
1-fenylethaan-1-on (1-fenylethylideen)hydrazon |
211-979-0 |
Skin Sens. 1 |
H317 |
GHS07 Wng |
H317 |
|
|
|
|
|
612-298-00-5 |
1,4-benzeendiamine, N,N'-gemengde fenyl- en tolylderivaten |
273-227-8 |
Repr. 1B Skin Sens. 1 |
H360FD H317 |
GHS08 GHS07 Dgr |
H360FD H317 |
|
|
|
|
|
613-088-00-6 |
1,2-benzisothiazool-3(2H)-on; 1,2-benzisothiazoline-3-on |
220-120-9 |
Acute Tox. 2 Acute Tox. 4 Skin Irrit. 2 Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 |
H330 H302 H315 H318 H317 H400 H410 |
GHS06 GHS05 GHS09 Dgr |
H330 H302 H315 H318 H317 H410 |
|
inademing: ATE = 0,21 mg/l (stofdeeltjes of nevels) oraal: ATE = 450 mg/kg lg Skin Sens. 1A; H317: C ≥ 0,036 % M = 1 M = 1 |
|
|
|
613-127-00-7 |
mepiquatchloride (ISO); 1,1-dimethylpiperidiniumchloride |
246-147-6 |
Acute Tox. 4 Acute Tox. 3 Aquatic Chronic 3 |
H332 H301 H412 |
GHS06 Dgr |
H332 H301 H412 |
|
inademing: ATE = 2,8 mg/l (stofdeeltjes of nevels) oraal: ATE = 270 mg/kg lg |
|
|
|
613-307-00-5 |
clothianidine (ISO); (E)-1-(2-chloor-1,3-thiazool-5-ylmethyl)-3-methyl-2-nitroguanidine |
433-460-1 |
Repr. 2 Acute Tox. 4 STOT SE 1 Aquatic Acute 1 Aquatic Chronic 1 |
H361f H302 H370 (zenuwstelsel) H400 H410 |
GHS08 GHS07 GHS09 Dgr |
H361f H302 H370 (zenuwstelsel) H410 |
|
oraal: ATE = 390 mg/kg lg M = 10 M = 100 |
|
|
|
613-346-00-8 |
4-nitrosomorfoline |
— |
Carc. 1B Muta. 2 STOT RE 1 |
H350 H341 H372 (lever) |
GHS08 Dgr |
H350 H341 H372 (lever) |
|
Carc. 1B; H350: C ≥ 0,001 % |
|
|
|
613-347-00-3 |
difenoconazool (ISO); 1-({2-[2-chloor-4-(4-chloorfenoxy)fenyl]-4-methyl-1,3-dioxolaan-2-yl}methyl)-1H-1,2,4-triazool; 3-chloor-4-[(2RS,4RS;2RS,4SR)-4-methyl-2-(1H-1,2,4-triazool-1-ylmethyl)-1,3-dioxolaan-2-yl]fenyl-4-chloorfenylether |
— |
Carc. 2 Acute Tox. 4 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H351 H302 H319 H400 H410 |
GHS08 GHS07 GHS09 Wng |
H351 H302 H319 H410 |
|
oraal: ATE = 1 450 mg/kg lg M = 10 M = 10 |
|
|
|
613-348-00-9 |
9-[2-(ethoxycarbonyl)fenyl]-3,6-bis(ethylamino)-2,7-dimethylxanthyliumchloride; Basic Red 1 |
213-584-9 |
Acute Tox. 3 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H301 H318 H317 H400 H410 |
GHS06 GHS05 GHS09 Dgr |
H301 H318 H317 H410 |
|
oraal: ATE = 280 mg/kg lg M = 10 M = 1 |
|
|
|
613-349-00-4 |
4-methylimidazool |
212-497-3 |
Carc. 1B Repr. 1B |
H350 H360Fd |
GHS08 Dgr |
H350 H360Fd |
|
|
|
|
|
615-051-00-X |
3,3'-dimethylbifenyl-4,4'-diyldiisocyanaat |
202-112-7 |
Carc. 2 Resp. Sens. 1 Skin Sens. 1A |
H351 H334 H317 |
GHS08 Dgr |
H351 H334 H317 |
|
Skin Sens. 1A; H317: C ≥ 0,001 % |
|
|
|
616-035-00-5 |
cymoxanil (ISO); 2-cyaan-N-[(ethylamino)carbonyl]-2-(methoxyimino)aceetamide; [1] (2E)-2-cyaan-N-[(ethylamino)carbonyl]-2-(methoxyimino)aceetamide; [2] |
261-043-0 [1] - [2] |
57966-95-7 [1] 166900-80-7 [2] |
Repr. 2 Acute Tox. 4 STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 |
H361fd H302 H373 (bloed, thymus, ogen) H317 H400 H410 |
GHS08 GHS07 GHS09 Wng |
H361fd H302 H373 (bloed, thymus, ogen) H317 H410 |
|
oraal: ATE = 360 mg/kg lg M = 1 M = 1 |
|
|
616-104-00-X |
benalaxyl (ISO); methyl-N-(2,6-dimethylfenyl)-N-(fenylacetyl)-DL-alaninaat |
275-728-7 |
Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 |
H302 H400 H410 |
GHS07 GHS09 Wng |
H302 H410 |
|
oraal: ATE = 1 000 mg/kg lg M = 1 M = 1 |
|
|
|
616-241-00-5 |
foramsulfuron (ISO); 2-{[(4,6-dimethoxypyrimidine-2-yl)carbamoyl]sulfamoyl}-4-formamido-N,N-dimethylbenzamide; 1-(4,6-dimethoxypyrimidin-2-yl)-3-(2-dimethylcarbamoyl-5-formamidofenylsulfonyl)ureum |
— |
Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 |
H351 H400 H410 |
GHS08 GHS09 Wng |
H351 H410 |
|
M = 1 000 M = 100 |
|
|
|
616-242-00-0 |
picolinafen (ISO); N-(4-fluorfenyl)-6-[3-(trifluormethyl)fenoxy]pyridine-2-carboxamide; 4′-fluor-6-[(α,α,α-trifluor-m-tolyl)oxy]picolinanilide |
— |
STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 |
H373 (bloed, schildklier) H400 H410 |
GHS08 GHS09 Wng |
H373 (bloed, schildklier) H410 |
|
M = 1 000 M = 1 000 |
|
|